Valeo Pharma (CSE: VPH-OTCQB: VPHIF) CEO Steve Saviuk joined Steve Darling from Proactive to bring news the Ontario Public Drug Program has said they will be listing Redesca and Redesca HP, its low molecular weight heparin biosimilar, on the Ontario Drug Benefit Formulary effective April 30, 2021.
Saviuk telling Proactive, Ontario represents 37% of the Canadian market and the listing of Redesca is a key milestone for the company. The company is now waiting for other provinces to do the same. Saviuk also shared with Proactive the details of their recent financing.